All News

Benson et al. Clinical features that predict CV risk in PsA. Median 3.53 year follow up. 56 CV events. 766 patients. Dactylitis emerged as key predictor in adjusted models. @RheumNow #ACR25 Abstr#2317 https://t.co/5O3G7vGYbq

Links:

Richard Conway RichardPAConway ( View Tweet)
IgG4-RD continues to present in new and unusual ways Hasbani et al. report 9 IgG4-RD patients with coronary artery involvement RCA and LAD most affected Seen on CTA Majority received RTX 7/9 pt at least partially improved imaging on f/u @RheumNow #ACR25 Abst 2531 https://t.co/Na0gdq3dgb

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
A new genetic score for ILD prediction! 🫁 Developed in the Veterans RA cohort and Validation in a Swedish cohort Model using classic RA-ILD risk factors and a cocktail of genetic risk A cut off of 0.05 in this cohort would exclude 36% from HRCT or PFTs Good performance https://t.co/6UsoSQAtyK

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Mateo Faxas et al. TriNetX study, propensity score matched. 3000 patients. Arrythmia risk is higher with IL-6i vs TNFi in diabetic RA patients. V Tachy (HR 1.4), PPM need (HR 1.4) significantly higher. AF, SVT, VF all numerically increased. @RheumNow #ACR25 Abstr#2283 https://t.co/U2Tk38Mobg

Links:

Richard Conway RichardPAConway ( View Tweet)
Effect of air pollution in RA Prospective cohort 1000+pts w/ 12000+ visits Higher levels of pollution & specific size of particles PM25 asso w/ -10% higher odd of flare -Higher DAS CRP and CDAI Now the interesting pattern: PM25 exposure increases 3 weeks before flares https://t.co/MOskJzk05g

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Management of cardiac and joint sarcoidosis. Use of TNFi in treatment refractory cases. Alana Nevares-Berrios @RheumNow #ACR25 https://t.co/hXOfkgQHP9

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#ACR25 Abstr#1608 10! 10! Across the board. 2-yr data from RCT + Open Label showed frequency of both airway and non-airway features of #EGPA improved with Benralizumab/Mepolizumab. Provides assurance to use more in real-world @RheumNow https://t.co/i78xXojGja

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
~1 in 6 pts with #sarcoidosis May have #cardiac involvemt 1/3 respond to #MTX + #steroids Followed by repeat #PET Failures get 👇 #infliximab >#adalimumab 👇 #JAKi Better survival >yrs ago R heart involved ⬆️risk of MTX nonresponse #ACR25 @RheumNow @ACRheum abst#1664 #ACRbest https://t.co/kYt9JRNSVH

Links:

Janet Pope Janetbirdope ( View Tweet)
New tx for IPF/autoimmune ILD, nerandomilast (PDE4Bi) Subgroup analysis from FIBRONEER-ILD, marginally less FVC worsening (-65mL tx grp vs -107mL plbo grp) & no clear improvements in dyspnea/fatigue/cough But also... 6% absolute reduction in overall, persisted (small n) in https://t.co/Faf26UZuDx

Links:

Mike Putman EBRheum ( View Tweet)
England et al. Predictors of progression RA-ILD - UIP pattern (HR 1.46), current (HR 1.98) and former (HR 1.60) smoking, age (HR 1.03). @RheumNow #ACR25 Abstr#1308 https://t.co/IvQo8Istta

Links:

Richard Conway RichardPAConway ( View Tweet)
What can we use to better predict MACE in RA patients? ESPOIR cohort showed value of two cardiac biomarkers: - hs-cTnT - soluble ST2 Combined, predicted MACE even after adjusting for disease activity/traditional CV RF. We need something like this! #ACR25 ABST1334 @RheumNow https://t.co/EUNDuuMaYD

Links:

David Liew drdavidliew ( View Tweet)
Loarce et al. Poor performance of CXR and PFT in diagnosing RA-ILD (compared to HRCT). Message is, if you think they have RA-ILD, you need to do CT. @RheumNow #ACR25 Abstr#1335 https://t.co/eeSTf72mvM

Links:

Richard Conway RichardPAConway ( View Tweet)
Who with #SSc-ILD will progress? progression is non linear - can stabilize and worsen Search for Predictive biomarker For clinical care & enriching RCTs Maybe #KL6 🤷‍♀️ Maybe IP-10, MIG No strong #biomarker Depends on what is used #ACR25 @RheumNow @ACRheum Abst#0882 #0883 https://t.co/lyTRUEY9SI

Links:

Janet Pope Janetbirdope ( View Tweet)
Don’t forget 👇 #lcSSc Pts can get and progress #ILD 1/3 of #limited #cutaneous #systemic #sclerosis #scleroderma GET ILD From #EUSTAR >14% progress Esp +Scl70 Remember to screen #CREST Pts & allow these Pts into lung disease trials #ACR25 @RheumNow @ACRheum abst#0879 https://t.co/X15tUgClzN

Links:

Janet Pope Janetbirdope ( View Tweet)
TriNetX database 4000+ pts PsA + GLP-1 RA & 86000+ PsA non GLP-1 ctrls Without much surprise GLP-1 treated pts had lower risk of MACE and death Observational, retrospective study. Now awaiting the prospective evidence. RCT on the way but capturing MACE and death are always https://t.co/GWbAMC1mJK

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Summary take home points by Dr Highland 1. PAH and PH-ILD are associated with high mortality in patients with SARDs 2. Multimodal and early screening is recommended 3. “It takes a village” work with Pulm and Cardiology colleagues @RheumNow #ACR2025 https://t.co/Xa7TecMOIe

Links:

Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Summary of (some) drugs in the pipeline for management of PAH. Slide credits: Dr Benjamin Freed ⁦@RheumNow⁩ #ACR2025 https://t.co/qazQNk4ovR

Links:

Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
In a global retrospective study of 90,536 PsA patients, those on GLP-1 receptor agonists (n=4,104) had significantly lower risk of major cardiovascular events and reduced mortality vs non-users. Most common GLP-1 RA: semaglutide. Supports future research on cardiometabolic https://t.co/ccOL10gD5b

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Time for the 2nd plenary session! 🎤 #0849 GLP-1 receptor agonists in #PsA linked with lower mortality & fewer major cardiac events in >90K patients. Promising data for inflammation, weight & heart health in PsA care. @RheumNow #ACR25 https://t.co/8zyrSrumOP

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
This morning in the plenary, same theme, but in PsA: Similar metabolic/CV concerns Similarly benefit from GLP-1 RA looking at TriNetX data again, reduced MACE Now prospective trials in rheum disease, for both metabolic benefits & disease activity? #ACR25 ABST0849 @RheumNow https://t.co/DHZN1hwbIG

Links:

David Liew drdavidliew ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×